HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 12/12/2012 -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has capitalized on a rejuvenated stock price with an $86.4 million financing deal that will pay for a Phase III confirmatory study of its hot candidate pimavanserin in Parkinson's disease. The developer's stock jumped 10.16% to $4.88 late this morning after news of the private placement of shares for $4.43 per share that is expected to close Dec. 17.
Is ACAD Ready To Move Back To New Highs This Year? Find Out Here
Zogenix, Inc. (NASDAQ:ZGNX) shares fell 3.45% to $1.12. The company announced that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) voted 2-11 [with 1 abstention] against the approval of ZohydroTM ER (hydrocodone bitartrate extended-release capsules), an extended-release formulation of hydrocodone without acetaminophen, for the management of moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Can MSFT Extend Rally? Find Out Here
BG Medicine, Inc. (NASDAQ:BGMD) are up 12.72% to $3.81 on trading volume of 5.4 million shares. The company’s stock continues to rally after the announcement before Tuesday’s market open that it obtained a CE Mark allowing for the commercial sale of a blood test to predict major cardiovascular issues. The 52-week high is $12.80.
What Should Investors Do With BGMD Now? Find Out Here
Incyte Corporation (NASDAQ:INCY) slid as well, trading down 7.29 percent to $16.54 after it was announced that Gilead Biosciences would be acquiring YM Biosciences for $510 million in cash. Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.
How Should Investors React To INCY Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)